Cargando…
Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabetes. Despite a significant reduction in major adverse CV events with SGLT2 inhibitor treatm...
Autores principales: | Tanaka, Atsushi, Node, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639481/ https://www.ncbi.nlm.nih.gov/pubmed/29025400 http://dx.doi.org/10.1186/s12933-017-0611-x |
Ejemplares similares
-
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020) -
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
por: Tanaka, Atsushi, et al.
Publicado: (2018) -
Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018) -
Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
por: Tanaka, Atsushi, et al.
Publicado: (2021) -
Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials
por: Tanaka, Atsushi, et al.
Publicado: (2019)